PAGE: 1

RAW SEQUENCE LISTING

PATENT APPLICATION US/09/450,073

Input Set: I450073.RAW

This Raw Listing contains the General Information Section and up to first 5 pages.



DATE: 12/13/1999

TIME: 16:45:15

```
<110> APPLICANT: Blaschuk, Orest W.
 1
           Symonds, James Matthew
 2
 3
           Gour, Barbara J.
 4
           Alexander, J. Steven
     <120> TITLE OF INVENTION: COMPOUNDS AND METHODS FOR CANCER THERAPY
     <130> FILE REFERENCE: 100086.405C2
 6
    <140> CURRENT APPLICATION NUMBER: US/09/450,073
 7
    <141> CURRENT FILING DATE: 1999-11-29
    <160> NUMBER OF SEQ ID NOS: 52
 9
    <170> SOFTWARE: PatentIn Ver. 2.0
10
                                                              ENTERED
    <210> SEQ ID NO 1
11
    <211> LENGTH: 4
12
    <212> TYPE: PRT
13
    <213> ORGANISM: Artificial Sequence
    <220> FEATURE:
15
    <223> OTHER INFORMATION: Description of Artificial Sequence: Occludin cell
16
           adhesion recognition sequence
17
     <400> SEQUENCE: 1
18
19
           Leu Tyr His Tyr
20
             1
21
    <210> SEQ ID NO 2
    <211> LENGTH: 10
23
    <212> TYPE: PRT
    <213> ORGANISM: Artificial Sequence
25
    <220> FEATURE:
    <223> OTHER INFORMATION: Description of Artificial Sequence: Cell adhesion
26
27
           modulating agent
    <400> SEQUENCE: 2
28
           Gln Tyr Leu Tyr His Tyr Cys Val Val Asp
29
30
31
    <210> SEQ ID NO 3
32
    <211> LENGTH: 6
    <212> TYPE: PRT
33
34
    <213> ORGANISM: Artificial Sequence
35
    <220> FEATURE:
    <223> OTHER INFORMATION: Description of Artificial Sequence: Cell adhesion
36
37
           modulating agent
38
    <220> FEATURE:
39
    <223> OTHER INFORMATION: Cyclic peptide
40
    <400> SEQUENCE: 3
41
           Cys Leu Tyr His Tyr Cys
42
            1
                             5
43
    <210> SEQ ID NO 4
    <211> LENGTH: 15
```

PAGE: 2 RAW SEQUENCE LISTING

PATENT APPLICATION US/09/450,073

Input Set: I450073.RAW

DATE: 12/13/1999

TIME: 16:45:15

<212> TYPE: PRT 45 <213> ORGANISM: Artificial Sequence 46 <220> FEATURE: 47 <223> OTHER INFORMATION: Description of Artificial Sequence: N-cadherin 48 cell adhesion recognition sequence 49 <400> SEQUENCE: 4 50 Phe His Leu Arg Ala His Ala Val Asp Ile Asn Gly Asn Gln Val 51 52 <210> SEQ ID NO 5 53 54 <211> LENGTH: 48 <212> TYPE: PRT 55 <213> ORGANISM: Homo sapiens 56 <400> SEQUENCE: 5 57 Gly Val Asn Pro Thr Ala Gln Ser Ser Gly Ser Leu Tyr Gly Ser Gln 58 59 Ile Tyr Ala Leu Cys Asn Gln Phe Tyr Thr Pro Ala Ala Thr Gly Leu 60 25 61 Tyr Val Asp Gln Tyr Leu Tyr His Tyr Cys Val Val Asp Pro Gln Glu 62 40 63 <210> SEQ ID NO 6 64 65 <211> LENGTH: 48 <212> TYPE: PRT 66 <213> ORGANISM: Mus musculus 67 <400> SEQUENCE: 6 68 Gly Val Asn Pro Thr Ala Gln Ala Ser Gly Ser Met Tyr Gly Ser Gln 69 70 Ile Tyr Met Ile Cys Asn Gln Phe Tyr Thr Pro Gly Gly Thr Gly Leu 71 72 Tyr Val Asp Gln Tyr Leu Tyr His Tyr Cys Val Val Asp Pro Gln Glu 73 40 74 75 <210> SEQ ID NO 7 76 <211> LENGTH: 48 77 <212> TYPE: PRT 78 <213> ORGANISM: Canis sp. <400> SEQUENCE: 7 79 Gly Val Asn Pro Thr Ala Gln Ala Ser Gly Ser Leu Tyr Ser Ser Gln 80 81 Ile Tyr Ala Met Cys Asn Gln Phe Tyr Ala Ser Thr Ala Thr Gly Leu 82 25 83 Tyr Met Asp Gln Tyr Leu Tyr His Tyr Cys Val Val Asp Pro Gln Glu 84 35 40 85 86 <210> SEQ ID NO 8 87 <211> LENGTH: 50 88 <212> TYPE: PRT <213> ORGANISM: dipodomys sp. 89 90 <400> SEQUENCE: 8 Gly Val Asn Pro Arg Ala Gly Leu Gly Ala Ser Ser Gly Ser Leu Tyr 91 10 92 Tyr Asn Gln Met Leu Met Leu Cys Asn Gln Met Met Ser Pro Val Ala 93 25 94 20

PAGE: 3 RAW SEQUENCE LISTING PATENT APPLICATION US/09/450,073

DATE: 12/13/1999 TIME: 16:45:15

Input Set: I450073.RAW

Gly Gly Ile Met Asn Gln Tyr Leu Tyr His Tyr Cys Met Val Asp Pro 95 96 Gln Glu 97 98 <210> SEQ ID NO 9 99 <211> LENGTH: 8 100 <212> TYPE: PRT 101 <213> ORGANISM: Artificial Sequence 102 <220> FEATURE: 103 <223> OTHER INFORMATION: Description of Artificial Sequence: 104 Representative occludin cell adhesion recognition 105 sequence 106 107 <400> SEQUENCE: 9 Leu Tyr His Tyr Leu Tyr His Tyr 108 109 <210> SEQ ID NO 10 110 <211> LENGTH: 15 111 112 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence 113 <220> FEATURE: 114 <223> OTHER INFORMATION: Description of Artificial Sequence: 115 Representative occludin cell adhesion recognition 116 sequence 117 <400> SEQUENCE: 10 118 Gln Leu Tyr His Tyr Gln Leu Tyr His Tyr Gln Leu Tyr His Tyr 119 10 120 5 <210> SEQ ID NO 11 121 <211> LENGTH: 10 122 123 <212> TYPE: PRT 124 <213> ORGANISM: Artificial Sequence <220> FEATURE: 125 126 <223> OTHER INFORMATION: Description of Artificial Sequence: Cell adhesion recognition sequence bound by N-cell adhesion 127 128 molecules <400> SEQUENCE: 11 129 Lys Tyr Ser Phe Asn Tyr Asp Gly Ser Glu 130 5 10 131 <210> SEQ ID NO 12 132 133 <211> LENGTH: 9 134 <212> TYPE: PRT 135 <213> ORGANISM: Artificial Sequence 136 <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Cell adhesion 137 138 modulation agent <400> SEQUENCE: 12 139 Tyr Leu Tyr His Tyr Cys Val Val Asp 140 141 <210> SEQ ID NO 13 142 <211> LENGTH: 8 143 <212> TYPE: PRT 144

PAGE: 4 RAW SEQUENCE LISTING
PATENT APPLICATION US/09/450,073

DATE: 12/13/1999 TIME: 16:45:15

Input Set: I450073.RAW

<213> ORGANISM: Artificial Sequence 145 146 <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Cell adhesion 147 modulation agent 148 <400> SEQUENCE: 13 149 Leu Tyr His Tyr Cys Val Val Asp 150 151 <210> SEQ ID NO 14 152 153 <211> LENGTH: 7 154 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence 155 <220> FEATURE: 156 <223> OTHER INFORMATION: Description of Artificial Sequence: Cell adhesion 157 modulation agent 158 159 <400> SEQUENCE: 14 160 Gln Tyr Leu Tyr His Tyr Cys 161 1 162 <210> SEQ ID NO 15 <211> LENGTH: 6 163 <212> TYPE: PRT 164 <213> ORGANISM: Artificial Sequence 165 <220> FEATURE: 166 <223> OTHER INFORMATION: Description of Artificial Sequence: Cell adhesion 167 modulation agent 168 169 <400> SEQUENCE: 15 Tyr Leu Tyr His Tyr Cys 170 171 172 <210> SEQ ID NO 16 173 <211> LENGTH: 5 174 <212> TYPE: PRT 175 <213> ORGANISM: Artificial Sequence 176 <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Cell adhesion 177 178 modulation agent 179 <400> SEQUENCE: 16 180 Leu Tyr His Tyr Cys 181 <210> SEQ ID NO 17 182 183 <211> LENGTH: 6 184 <212> TYPE: PRT 185 <213> ORGANISM: Artificial Sequence 186 <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Cell adhesion 187 188 modulation agent 189 <400> SEQUENCE: 17 190 Gln Tyr Leu Tyr His Tyr 191 192 <210> SEQ ID NO 18 193 <211> LENGTH: 5

194

<212> TYPE: PRT

PAGE: 5 RAW SEQUENCE LISTING DATE: 12/13/1999

PATENT APPLICATION US/09/450,073

Input Set: I450073.RAW

TIME: 16:45:15

<213> ORGANISM: Artificial Sequence 195 <220> FEATURE: 196 <223> OTHER INFORMATION: Description of Artificial Sequence: Cell adhesion 197 198 modulation agent <400> SEQUENCE: 18 199 Tyr Leu Tyr His Tyr 200 1 201 202 <210> SEQ ID NO 19 <211> LENGTH: 10 203 <212> TYPE: PRT 204 <213> ORGANISM: Artificial Sequence 205 206 <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Cell adhesion 207 208 modulation agent 209 <400> SEQUENCE: 19 Cys Asp Gly Tyr Pro Lys Asp Cys Lys Gly 210 5 211 <210> SEQ ID NO 20 212 <211> LENGTH: 10 213 <212> TYPE: PRT 214 <213> ORGANISM: Artificial Sequence 215 216 <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Cell adhesion 217 218 modulation agent <220> FEATURE: 219 <223> OTHER INFORMATION: Cyclic Peptide 220 221 <400> SEQUENCE: 20 Cys Asp Gly Tyr Pro Lys Asp Cys Lys Gly 222 5 223 <210> SEQ ID NO 21 224 225 <211> LENGTH: 10 226 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence 227 228 <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Cell adhesion 229 modulation agent 230 231 <400> SEQUENCE: 21 Cys Gly Asn Leu Ser Thr Cys Met Leu Gly 232 233 -5 <210> SEO ID NO 22 234 235 <211> LENGTH: 10 236 <212> TYPE: PRT 237 <213> ORGANISM: Artificial Sequence 238 <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Cell adhesion 239 240 modulation agent 241 <220> FEATURE: <223> OTHER INFORMATION: Cyclic Peptide 242 243 <400> SEQUENCE: 22 Cys Gly Asn Leu Ser Thr Cys Met Leu Gly

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

PAGE: 6

VERIFICATION SUMMARY PATENT APPLICATION US/09/450,073

DATE: 12/13/1999 TIME: 16:45:15

Input Set: **I450073.RAW**

Line	?	Error/Warning							Original Text										
	-														· 				
354	W	"N"	or	"Xaa"	used:	Feature	required	Cys	Leu	Tyr	His	Tyr	Xaa						
370	W	"N"	or	"Xaa"	used:	Feature	required	Xaa	Leu	Tyr	His	Tyr	Cys						
386	W	"N"	or	"Xaa"	used:	Feature	required	Xaa	Leu	Tyr	His	Tyr	Cys						
402	W	"N"	or	"Xaa"	used:	Feature	required	Xaa	Leu	Tyr	His	Tyr	Cys						
419	W	"N"	or	"Xaa"	used:	Feature	required	Xaa	Leu	Tyr	His	Tyr	Cys						
568	W	"N"	or	"Xaa"	used:	Feature	required	Gly	Val	Asn	Pro	Thr	Ala	Gln	Xaa	Gly	Ala	S	
570	W	"N"	or	"Xaa"	used:	Feature	required	Xaa	Ser	Gln	Ile	Tyr	Xaa	Xaa	Cys	Asn	Gln	Ρ	
572	W	"N"	or	"Xaa"	used:	Feature	required	Thr	Gly	Leu	Tyr	Xaa	Asp	Gln	Tyr	Leu	Tyr	Н	
611	W	"N"	or	"Xaa"	used:	Feature	required	Trp	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Gly				
							required	Xaa	Phe	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Gly			